Non-existence of a positive correlation between urinary levels of α1- microglobulin and ulinastatin in patients with Parkinson's disease

Psychiatry and Clinical Neurosciences

Volumn 50, Issue 4, 1996, Pages 231-233

  Inagaki, Takuji ^a   Shikimi, Tadahiro ^a   Matsubara, Kazuo ^a   Kobayashi, Shoutai ^a   Ishino, Hiroshi ^a   Okunishi, Hideki ^a   Takaori, Shuji ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Parkinson's disease; ulinastatin; urine; 1M

Indexed keywords

ALPHA 1 MICROGLOBULIN; CREATININE; ULINASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEMENTIA; FEMALE; HUMAN; MALE; MOOD; PARKINSON DISEASE; SCHIZOPHRENIA; URINE LEVEL;

EID: 0029837480     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1996.tb02747.x     Document Type: Article

References (8)

1. 1-microglobulin. Trends Biochem. Sci. 1990; 15: 240-243.
2. Shikimi T, Hattori K, Takaori S. Effects of heparin on the inhibitory activities of human urinary trypsin inhibitor (ulinastatin) on trypsin, chymotrypsin and leukocyte elastase. Jpn. J. Pharmacol. 1993; 62: 115-118.
3. 1-microglobulin to ulinastatin levels in patients with Alzheimer-type dementia and vascular dementia. Psychiatry Clin. Neurosci. 1995; 49: 287-290.
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
5. Shikimi T, Suzuki S, Takahashi M, Kaneto H. Sandwich enzyme-immunoassay of human urinary trypsin inhibitor (urinastatin) and urinastatin-like immunoreactive substance in mouse urine. Scand. J. Clin. Lab. 1990; 50: 1-8.
6. Shikimi T, Himeno Y, Shigeno K et al. Relationships between ulinastatin and alpha-1-microglobulin in human urine. Clin. Chim. Acta. 1994; 227: 195-200.
7. Salier JP, Verga V, Doly J, Diarra-Mehrpour M, Erickson RP. The genes for the inter-α-inhibitor family share a homologous organization in human and mouse. Mammal Genome 1992; 2: 233-239.
8. Arai N, Misugi K, Goshima Y, Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MRTP)-treated C57 black mouse model for parkinsonism. Brain Res. 1990; 515: 57-63.